Testosterone Antidepressant Augmentation in Women
Testosterone Antidepressant Augmentation in Women
The investigators' hypotheses are: Low-dose testosterone augmentation improves depressive
 symptoms in women with Major Depressive Disorder (MDD) and antidepressant
 partial/nonresponse, adjunctive low-dose testosterone is safe and well-tolerated in women
 with MDD and antidepressant partial/nonresponse, and low-dose testosterone augmentation
 improves fatigue and sexual dysfunction.
Inclusion Criteria:

 1. Female, age 21-75

 2. Major depressive disorder including MADRS>/=12

 3. Currently treated with an antidepressant monotherapy (1st, 2nd or 3rd trial in current
 episode), that has been taken at an adequate dose for at least six weeks.

 Exclusion Criteria:

 1. Serious suicide or homicide risk, as assessed by evaluating clinician

 2. Unstable medical illness including cardiovascular, hepatic, renal, respiratory,
 endocrine, neurologic

 3. Substance use disorder active within last six months, or clinical suspicion of ongoing
 substance use disorder at the discretion of the study clinician at time of screening
 based on history and/or laboratory results.

 4. Any history of psychotic features, bipolar disorder, or primary obsessive compulsive
 disorder, as assessed by SCID

 5. Currently treated with typical or atypical antipsychotic medications, or lithium

 6. Untreated hypothyroidism. If treated hypothyroidism, change in levothyroxine dose
 within the prior 3 mos

 7. Use of androgens, including testosterone, dehydroepiandrosterone (DHEA) and
 methyltestosterone, within the prior three months

 8. Any investigational psychotropic drug within the last thirty days

 9. In the judgment of the study clinician, unlikely to be able to participate safely
 throughout the study period (three or more episodes of self-harm in the past year,
 documented history of poor treatment adherence, or frequent missed appointments (>50%)
 in the past year)

 10. ALT > 3x upper limit of normal or creatinine> 3x upper limit

 11. History of a hormone-responsive cancer